The novel technology by Prof. Nissim Benvenisty utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs
Qlight Nanotech’s staff will remain at the Company’s site at the Hebrew University of Jerusalem, and will function as the research base for Merck for quantum-materials for the display and lighting industry
Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of advanced materials with ICL (NYSE and...
Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission. Ikervis is approved for treatment of severe keratitis in adult patients with dry eye...
The invention to be presented at Agritech Israel 2015
The licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists, Raphael Mechoulam, Professor of medicinal chemistry, and Ruth Gallily, Professor of immunology, both from the...
Phytotech Medical went public on the Australian Securities Exchange raising AUS$5.9 million dollars
Prize awarded for contribution to collaboration between Melodea and Holmen
Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, announced today that it has received US $3 million investment from Guangxi Wuzhou Pharmaceutical Group Co.,...
Yaacov Michlin, CEO of Yissum, said at the signing ceremony: “The framework agreement we signed today sets the ground for a wide range of potential areas of research collaboration between the two parties”.
The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016
Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections